PUBLISHER: Grand View Research | PRODUCT CODE: 1433598
PUBLISHER: Grand View Research | PRODUCT CODE: 1433598
The global photodynamic therapy devices market size is anticipated to reach USD 1,002.94 million by 2030, and it is projected to grow at a CAGR of 8.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth and widespread adoption of PDT devices can be attributed to various key factors. Among these, a primary driving force is the increasing prevalence of cancer and dermatological disorders, leading to a heightened demand for non-invasive and effective treatment options. The global surge in skin cancers, encompassing conditions like basal cell carcinoma and squamous cell carcinoma, has created a demand for efficient treatment methods such as PDT.
In February 2022, data from the World Health Organization (WHO) highlighted that cancer accounted for 10 million deaths worldwide, constituting approximately one in six fatalities in 2020. The number of cancer diagnoses exceeded the number of deaths from cancer. Furthermore, the rising application of photodynamic therapy in conditions such as breast cancer, lung cancer, and others is expected to further propel the segment's growth throughout the forecast period.
Furthermore, key market players play a pivotal role in propelling the market growth. For instance, in August 2022, Asieris Pharmaceuticals marked a significant milestone with the completion of its multinational Phase III Clinical Trial of Cevira (APRICITY). Cevira represents an innovative photodynamic drug-device combination product specifically crafted for the non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL). The engagement of market players and their novel advancements underscores the dynamic nature and continual progress within market.